Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Amorphous Pharmaceutical Materials |
 |
 |
 |
|
Amorphous Pharamaceutical Materials Amorphous Molecular Solids: Features and Stability by Marc Descamps
Although running as seperate events Pharmaceutical Co-Crystals and Amorphous Pharmaceutical Materials will be running back to back in Amsterdam next year. We will one again be offering excellent updates to all those involved in Solid States. Amorphous Materials 2008 September 25th - 26th 2008. Venue to be confirmed, Amsterdam, The Netherlands. This Amorphous Conference will include new options for drug development and provide attendees with an unrivalled paltform from which to launch new ideas. Also hear from industry leaders as to which amorphous forms of drugs the have developed and why. Learn from their case studies how they stabilised and controlled these forms and what they are used for now. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis